Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)
 
 • Company Description   
Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

Number of Employees: 155

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.70 Daily Weekly Monthly
20 Day Moving Average: 2,579,676 shares
Shares Outstanding: 108.39 (millions)
Market Capitalization: $617.85 (millions)
Beta: 1.63
52 Week High: $12.02
52 Week Low: $1.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 27.52% 23.69%
12 Week 314.55% 259.35%
Year To Date 84.47% 74.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
201 BROOKLINE AVE. SUITE 901
-
BOSTON,MA 02215
USA
ph: 857-320-4900
fax: -
ir@tangotx.com http://www.tangotx.com
 
 • General Corporate Information   
Officers
Barbara Weber - Chief Executive Officer; President and Director
Alexis Borisy - Chairman
Daniella Beckman - Chief Financial Officer
Lesley Ann Calhoun - Director
Kanishka Pothula - Director

Peer Information
Tango Therapeutics, Inc. (CORR.)
Tango Therapeutics, Inc. (RSPI)
Tango Therapeutics, Inc. (CGXP)
Tango Therapeutics, Inc. (BGEN)
Tango Therapeutics, Inc. (GTBP)
Tango Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87583X109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 108.39
Most Recent Split Date: (:1)
Beta: 1.63
Market Capitalization: $617.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.36 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.70
Price/Cash Flow: -
Price / Sales: 15.07
EPS Growth
vs. Year Ago Period: -2.86%
vs. Previous Quarter: -2.86%
Sales Growth
vs. Year Ago Period: -16.67%
vs. Previous Quarter: 30.97%
ROE
06/30/25 - -
03/31/25 - -62.75
12/31/24 - -55.40
ROA
06/30/25 - -
03/31/25 - -39.94
12/31/24 - -35.78
Current Ratio
06/30/25 - -
03/31/25 - 6.26
12/31/24 - 6.98
Quick Ratio
06/30/25 - -
03/31/25 - 6.26
12/31/24 - 6.98
Operating Margin
06/30/25 - -
03/31/25 - -322.67
12/31/24 - -309.73
Net Margin
06/30/25 - -
03/31/25 - -322.67
12/31/24 - -309.73
Pre-Tax Margin
06/30/25 - -
03/31/25 - -322.17
12/31/24 - -309.24
Book Value
06/30/25 - -
03/31/25 - 1.54
12/31/24 - 1.86
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©